Seek Labs Expands Oncology Research for Sequence Ablation Therapeutics with Up to $3 Million in Foundation Support

Skip to Content News Archives Economy Defence Energy Oil & Gas Renewables Electric Vehicles Mining Commodities Agriculture Real Estate Mortgages Mortgage Rates Finance Banking Insurance Fintech Cryptocurrency Defence Work Wealth Smart Money Wealth Management Investor Personal Finance Family Finance Retirement Taxes High Net Worth FP Comment Executive Women Puzzmo Newsletters Financial Times Business Essentials More Innovation Information Technology FP500 Podcasts Small Business Lives Told Tails Told Shopping Financial Post Store Obituaries Place a Notice Advertising Advertising With Us Advertising Solutions Postmedia Ad Manager Sponsorship Requests Classifieds Place a Classifieds ad Working Profile Settings My Subscriptions My Offers Newsletters Customer Service FAQ News Economy Energy Mining Real Estate Finance Defence Work Wealth Investor FP Comment Executive Women Puzzmo Newsletters Financial Times Business Essentials This advertisement has not loaded yet, but your article continues below.HomeGlobeNewswireThis section is The content in this section is supplied by GlobeNewswire for the purposes of distributing press releases on behalf of its clients. Postmedia has not reviewed the content. by GlobeNewswire Seek Labs Expands Oncology Research for Sequence Ablation Therapeutics with Up to $3 Million in Foundation SupportAuthor of the article:Two2Ten Foundation supports the continued development of Seek Labs’ Sequence Ablation Therapeutics (SAT) platform into oncology, honoring the memory of Travis SnyderTHIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLYSubscribe now to read the latest news in your city and across Canada.Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman, and others.Daily content from Financial Times, the world's leading global business publication.Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.Daily puzzles, including the New York Times Crossword.SUBSCRIBE TO UNLOCK MORE ARTICLESSubscribe now to read the latest news in your city and across Canada.Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman and others.Daily content from Financial Times, the world's leading global business publication.Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.Daily puzzles, including the New York Times Crossword.REGISTER / SIGN IN TO UNLOCK MORE ARTICLESCreate an account or sign in to continue with your reading experience.Access articles from across Canada with one account.Share your thoughts and join the conversation in the comments.Enjoy additional articles per month.Get email updates from your favourite authors.THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK.Create an account or sign in to continue with your reading experience.Access articles from across Canada with one accountShare your thoughts and join the conversation in the commentsEnjoy additional articles per monthGet email updates from your favourite authorsSign In or Create an AccountSALT LAKE CITY, Oct. 26, 2026 (GLOBE NEWSWIRE) — Seek Labs, a Salt Lake City Tech Bio company developing programmable CRISPR-based medicines, today announced an agreement with the Two2Ten Foundation providing up to $3 million to support the continued expansion of its Sequence Ablation Therapeutics (SAT) platform into oncology. The funding will advance preclinical research applying Seek Labs’ programmable therapeutic approach to cancer with the goal of creating new options for patients underserved by existing treatments.This advertisement has not loaded yet, but your article continues below.A mission rooted in a family’s experienceThe collaboration reflects a shared conviction that existing treatments leave too many patients without effective options and that advancing cancer care requires investment in new therapeutic approaches. For Heidi Snyder, President of the Two2Ten Foundation, that mission is personal. Her husband, Travis Snyder, passed away from acute myeloid leukemia.Get the latest headlines, breaking news and columns.By signing up you consent to receive the above newsletter from Postmedia Network Inc.A welcome email is on its way. If you don't see it, please check your junk folder.The next issue of Top Stories will soon be in your inbox.We encountered an issue signing you up. Please try againHeidi Snyder said, “The next generation of cancer treatments will come from people willing to think differently. Travis’s experience made it impossible for me to believe today’s treatment options are the best we can do. Seek Labs is pursuing an unconventional approach to targeting cancer, with the potential to open entirely new possibilities in oncology. That’s the kind of ambitious science we believe deserves support—and the kind of work we want Travis’s legacy to help advance.”Expanding a programmable approach to diseaseSequence Ablation Therapeutics are investigational medicines designed to recognize and ablate selected genetic sequences involved in disease. The platform combines computational sequence analysis with programmable CRISPR technology to develop therapeutic candidates for specific disease targets.This advertisement has not loaded yet, but your article continues below.“We built Seek Labs because too many families reach a point where medicine has no more answers for them,” said Jared Bauer, CEO and Co-Founder of Seek Labs. “The treatments available today have changed many lives, but there are still patients they cannot help. We see an important opportunity to expand SAT into oncology and explore a different approach to treating cancer. We are grateful to Heidi and the Foundation for helping us advance that work in Travis’s memory.”Advancing oncology researchSeek Labs is exploring how SAT can be applied in oncology, building on the company’s broader work in infectious disease. The Foundation’s support will advance research into SAT candidates and their delivery. The findings will guide subsequent development.“Expanding SAT into oncology opens an important new direction for our research,” said Alison O’Mahony, PhD, Senior Vice President of Research and Development at Seek Labs. “We are excited by the opportunity to bring our platform to cancers where patients urgently need better options. This funding allows us to move that work forward and investigate what a programmable approach could make possible.”This advertisement has not loaded yet.This advertisement has not loaded yet, but your article continues below.The program will evaluate SAT in preclinical cancer models, generating evidence to inform the platform’s development in oncology. Seek Labs intends to share findings through scientific publications and presentations as the research progresses.About Seek LabsSeek Labs is a Salt Lake City Tech Bio company building programmable platforms for detecting and treating disease. Its Sequence Ablation Therapeutics platform combines genomic discovery, computational sequence analysis and CRISPR technology to develop investigational medicines directed at genetic sequences involved in disease. The company is advancing research across infectious disease and oncology. Learn more at https://seeklabs.com.About the Two2Ten FoundationThe Two2Ten Foundation is a nonprofit organization focused on emerging technologies with the potential to transform cancer treatment. Its support of Seek Labs’ research honors the memory of Travis Snyder and helps advance the exploration of new therapeutic approaches. Learn more at https://two2ten.orgInvestigational statusSequence Ablation Therapeutics are investigational and have not been approved by the U.S. Food and Drug Administration or any other regulatory authority. The oncology program is in preclinical research. Safety and efficacy in humans have not been established.Media contactKim WirthlinSeek Labskim@seeklabs.com+1 385 270 9887 ext. 0115This advertisement has not loaded yet.Notice for the Postmedia NetworkThis website uses cookies to personalize your content (including ads), and allows us to analyze our traffic. Read more about cookies here. By continuing to use our site, you agree to our Terms of Use and Privacy Policy.